Why is Oxford-AstraZeneca Vaccine Looking Like India’s Best Shot?

Even as India battles a big spike in COVID cases, the good news is that vaccine developers are closer to success.

1 min read

Even as India battles a big spike in COVID cases, forcing some states to reimpose certain restrictions on people's movements, the good news is that vaccine developers are inching towards success at a rapid pace.

Recently, the COVID-19 vaccine being developed by the University of Oxford and Swedish-British pharma AstraZeneca was announced to have 70 percent efficacy after a large-scale trial. This of course comes on the heels of a string of announcements from other research groups:

  • Pfizer's announcement from 9 November, of the interim results of its candidate vaccine proving to be more than 90 percent effective (which they later revised to 95 percent).
  • Russia's announcement that came on 11 November, on Sputnik V showing 92 percent efficacy in late-stage trials,
  • And Moderna's announcement from 16 November about its candidate's 94.5 percent efficacy.

And not to mention India's very own candidate COVAXIN being developed by Bharat Biotech, who, on 23 November, said that the vaccine is expected to be 60 percent efficacious.

What do these different levels of efficacy mean for us in this vaccine race? Why is the Oxford-Astrazeneca vaccine looking like India's best shot? Tune in to The Big Story!

(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)

Read and Breaking News at the Quint, browse for more from podcast

Speaking truth to power requires allies like you.
Become a Quint Insider

or more


3 months
12 months
12 months
Check Insider Benefits
Read More
Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!
More News